Allarity Therapeutics, Inc.

ALLR

NASDAQ

Healthcare

Biotechnology

Boston, MA, US6 employeesallarity.com

$1.17

+0.04(3.54%)

Mkt Cap $19M

$0.70

$1.97

52-Week Range

At a Glance

AI-generated

Allarity Therapeutics significantly reduced its operating and net losses in FY2025 through strategic cost restructuring and a narrowed clinical focus, though it remains a pre-revenue company facing substantial ongoing expenses and cash burn as it advances its lead candidate.

Revenue breakdown: License (100%).

8-K

Allarity Therapeutics reported a reduced net loss of $11.2 million for FY 2025 and strengthened its balance sheet with a $20 million debt financing in March 2026, extending cash runway to mid-2028.

$19M

Market Cap

—

Revenue

-$17M

Net Income

Employees6

Fundamentals

How The Business Makes Money

Revenue by Segment

License100%($320.0K)

Activity

What Changed Recently

Financial Results

Mar 31, 2026

Results of Operations and Financial Condition.** On March 31, 2026, Allarity Therapeutics, Inc. (the “Company”) issued a press release announcing its financial

Material Agreement

Mar 5, 2026

Entry into a Material Definitive Agreement. On March 2, 2026, Allarity Therapeutics, Inc., a Delaware corporation (the “ Company ”) entered into a note purchase

Material Agreement

Jan 28, 2026

Entry into a Material Definitive Agreement. Equity Line of Credit Common Stock Purchase Agreement On January 28, 2026, Allarity Therapeutics, Inc. (the “ Compan

Other Event

Mar 8, 2026

Other Matters. On March 6, 2026, Allarity Therapeutics, Inc. (the “Company”) announced the closing of a $20 million non-convertible debt financing with Streeter

Other Event

Feb 18, 2026

Other Matters. On February 18, 2026, Allarity Therapeutics, Inc. (the “Company”) announced that the first patients have been dosed with stenoparib and temozolom

Peer Companies

Company	Price	Change	Market Cap	P/E
CINGCingulate Inc.	$6.20	+3.08%	$35M	-1.7
LEXXLexaria Bioscience Corp.	$1.04	+20.08%	$20M	-1.4
LIXTLixte Biotechnology Holdi...	$3.14	+2.45%	$14M	-4.0
ENTOENTO	$2.85	-5.00%	$14M	—
KAPAKairos Pharma, Ltd.	$0.59	+1.97%	$12M	—
BCTXBriaCell Therapeutics Cor...	$4.08	-1.57%	$8M	-0.3
CRISCuris, Inc.	$0.55	+3.19%	$7M	-12.8
PCSAProcessa Pharmaceuticals,...	$2.83	+8.72%	$6M	-0.4

Analyst View

Company Profile

CIK0001860657

ISINUS0167445008

CUSIP016744500

Phone401 426 4664

Address210 Broadway, Boston, MA, 02139, US

SEC EDGAR